GAIA and Orexo terminate agreement for deprexis® in the USA
Hamburg, December 04, 2024
GAIA AG and Orexo AB have decided to mutually terminate the deprexis® partnership agreement covering the rights for Orexo to commercialize the digital mental health program for depression in the USA.
GAIA and Orexo deem it is in the best interest of the companies and patients in the USA, for GAIA to reclaim the commercial rights for deprexis®. With 16 RCTs, 2 Meta Analysis and over 150.000 patients treated to date, both the scientific and clinical evidence of deprexis® is unparalleled in the world of digital therapeutics. Moving forward, GAIA will continue to partner with Orexo in the area of substance abuse as it pursues new commercial options for deprexis®.
Mario Weiss, CEO of GAIA:
“deprexis® is the global leader in both evidence and number of patients treated. We are convinced that there is no other digital therapeutic that can so effectively be used for adults with mild, moderate and severe unipolar depression. We are therefore very pleased with the recent policy announcement from the Centers for Medicare and Medicaid Services (CMS) enabling reimbursement of digital health programmes and will intensify our partnering efforts to provide even more patients with access to deprexis® in the US.”
Nikolaj Sorensen, CEO of Orexo AB adds:
“deprexis® is a fantastic product with best in class evidence and as much as we welcome the new CMS announcement, we want to concentrate on leveraging the opportunity with regards to this new policy in our core area of expertise in the USA - substance abuse.”
Therefore both parties agreed that GAIA would be better positioned with a partner with a strong footprint in depression to leverage the full potential of deprexis®.
About GAIA:
GAIA is a global leader in the development of evidence-based, fully-automated digital therapy systems that have benefited patients, physicians, and insurers for over two decades. Its product portfolio includes not only digital health applications (DiGA) but also numerous innovative therapeutics for mental health conditions, as well as other therapeutic areas such as immunology, rheumatology, MS, and back pain.
For over 25 years, GAIA has combined scientific, technological, and therapeutic expertise under one roof. Its goal is to support as many people as possible in restoring and maintaining their mental and physical health, thus improving their quality of life and well-being. The expert team at GAIA has confirmed the efficacy of its products in over 30 RCTs and meta-analyses. GAIA is the 48th member of the Association of Research-Based Pharmaceutical Companies (vfa). For more information, visit www.gaia-group.com/en.
For licensing and media inquiries, please contact:
Stan Sugarman
GAIA AG
Hans-Henny-Jahnn-Weg 53
22085 Hamburg
E-Mail: presse@gaia-group.com
Telefon: +49 40 3510520
